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Abstract 
Purpose: To examine the clinical effect of Fuzheng Quyu therapy in patients undergoing radiotherapy 
after cervical carcinoma surgery.   
Methods: One hundred and twenty patients who underwent radiotherapy after cervical carcinoma 
surgery were selected randomly and divided evenly into control and study groups. Patients in the control 
group underwent radiotherapy only, whereas those in the study group received treatment designed to 
nourish healthy vital energy and eliminate blood stasis in addition to radiotherapy. Changes in the 
coagulation index of the two groups were recorded after treatment. The clinical effects and the 
incidence of adverse events were compared between the groups. 
Results: The plasma prothrombin time and activated partial thromboplastin time improved after 
treatment in the study group to greater extents than in the control group. The levels of D-dimer, blood 
platelets and fibrinogen were lower after treatment in the study group than in the control group (p < 
0.05). Improvement in Karnofsky Performance Score and quality of life score of the study group was 
superior to that of the control group. The proportion of patients who required drug intervention was 
much lower in the study group (0.83 %) than in the control group (28.33 %) (p < 0.05). The incidence of 
adverse reactions was much lower in the study group (6.7 %) than in the control group (35.0 %, p < 
0.05). 
Conclusion: Herbal therapy designed to nourish vital energy and eliminates blood stasis relieves high-
level blood coagulation, and also improves quality of life (QoL) in patients undergoing radiotherapy after 
cervical carcinoma surgery, thus suggesting its potential clinical applications. 
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Cervical carcinoma is a frequent malignant 
disease in women that threatens both health and 
lives; its incidence is second only to that of 
breast cancer [1]. Currently, radiotherapy and 
surgical therapy are the standard treatments for 
patients with cervical carcinoma. However, some 
patients cannot tolerate radiotherapy, its duration 
is long, and it can cause various dangerous side 
effects and lower the quality of life (QoL) [2,3]. 
Studies [4,5] have indicated that radiation 
damages normal tissues while killing tumour 
cells, and it may induce short-term radiotherapy 
reactions and long-term complications. 
Moreover, some tumour cells are relatively 
insensitive to radiation, and the curative effect of 
radiotherapy may not be satisfactory, particularly 
in young patients with cervical carcinoma who 
require high postoperative QoL and hope to 
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retain normal endocrine function and a sexual 
life, as radiotherapy can damage ovarian 
function. Hence, it is important to discuss 
alternative safe and effective therapies for 
cervical carcinoma. 
 
Traditional Chinese Medicine (TCM) oncology 
has attracted increasing attention, and TCM 
plays an important role in the treatment of 
malignant tumours in females. Many clinical and 
experimental studies have demonstrated that 
TCM combined with radiotherapy or 
chemotherapy reduces toxicity and enhances 
efficacy [6,7]. Based on clinical practice and the 
characteristics of TCM oncology, this study 
developed a Chinese herbal compound to 
nourish vital energy and eliminate blood stasis 
following TCM dialectics and governmental 
ethical guidelines and evaluated its effect in 
patients undergoing radiotherapy, aiming to 





This study was approved by the medical ethics 
committee of the First Affiliated Hospital of 
Zhengzhou University (approval no: 
LMZ20150615) and followed the Decla-
ration of Helsinki [8]. Patients (120) who 
underwent radiotherapy after cervical carcinoma 
surgery at the First Affiliated Hospital, 
Zhengzhou University, Henan, China from May 
2011 to May 2014 were randomly selected and 
divided into a study group and a control group (n 
= 60/group). Patients in the study group were 
aged 24 – 60 years (mean, 30.20 ± 1.20 years); 
there were 54 cases of squamous carcinoma and 
6 of adenocarcinoma. In the control group, 
patients were aged 25 – 62 years (mean, 30.30 ± 
1.30 years); there were 56 cases of squamous 
carcinoma and four of adenocarcinoma. The 
general data showed no difference between the 
two groups (p > 0.05); thus, the results are 
comparable. 
 
Patients included in the study had cervical 
carcinoma, underwent radiotherapy after cervical 
carcinoma surgery, had Karnofsky Performance 
Scores (KPSs) > 60, had at least 6 months’ 
survival time, were aged 20 – 70 years, 
volunteered to participate in the study, and 
signed informed consent forms. Those who had 
severely impaired organ function or mental 
diseases, those who stopped taking the medicine 
or did not take the medicine for a sufficient time, 
and pregnant or nursing women were excluded. 
 
Patients in the study group were treated with 
radiotherapy and Fuzheng Quyu therapy. The 
specific procedures were as follows. A linear 
accelerator was used for long-distance 
irradiation. The upper boundary was set at the 
L4–5 intervertebral disc, and the lower boundary 
at the inferior margin of obturator foramen; the 
space between the left and right pelvic bones 
was 1.5 cm.  
 
Irradiation was performed five times per week, at 
2 Gy each time, for a total of 20 – 25 treatments. 
Fuzheng Quyu preparation contained 30 g of 
Chinese yam, 25 g of Astragalus 
membranaceus, 25 g of Codonopsis pilosula, 20 
g of Angelica sinensis, 20 g of Lycium barbarum, 
15 g of Rehmannia glutinosa Libosch, 15 g of 
peony tree root bark, 15 g of rhizoma sparganii, 
one centipede, and one Buthus martensii Karsch. 
Different medicines were added according to 
clinical symptoms. White atractylodes, Poria 
cocos, and Schisandra chinensis were added for 
patients who showed a yellow facial complexion, 
abdominal distension, diarrhoea, and fatigue. 
Polygonatum odoratum and rhizoma 
anemarrhenae were added if patients had 
symptoms of dizziness, tinnitus, parched mouth 
and tongue, and insomnia. Colla corii asini and 
Caulis Spatholobi were added if patients were 
weak or fainted when they stood up. Those who 
felt cold in the limbs and had frequent micturition 
at night were given Curculigo orchioides and 
herba epimedii.  
 
The medicine was decocted in water; 1000 mL of 
water was added during the first decoction, and 
patients took 100 mL of the resulting broth; 500 
mL of water was added during the second 
decoction, and 100 mL of broth was taken. 
Ingredients for the broth were combined and 
mixed twice, and the broth was taken by patients 
twice daily (morning and evening) on the day of 
radiotherapy. The medication was stopped when 
radiotherapy was completed. Patients in the 
control group were treated with radiotherapy 
using the same treatment as those in the study 
group. Changes in routine blood indices were 
observed during treatment. Symptomatic 





First was coagulation indicator. Fasting venous 
blood samples (3 mL) were collected in the 
morning, transferred to anticoagulant-containing 
tubes and centrifuged at 3,000 revolutions/min 
for 10 min. The yellow plasma (the upper layer) 
was collected and stored at 2 – 8 °C. The 
activated partial thromboplastin time (APTT) was 
measured using the Compact BE fully automatic 
coagulometer. The D-dimer level was measured 
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using a colloid gold immunofiltration assay. 
Platelet counts were determined using the 
Nanjing Pulang XFA9500 five-classification, fully 
automatic blood analyzer. Plasma prothrombin 
time (PT) was determined using the Beijing Precil 
C2000-1 semi-automatic coagulometer. Other 
data, including QOL scores and KPSs, were also 
recorded both before and after treatment. QOL 
was determined using a QOL scale, in which a 
higher score indicated a better QOL. KPS was 
determined using recognised scoring criteria, in 
which a higher score indicated a better physical 
condition. The symptomatic treatment outcomes 
were observed in the two groups. Adverse 




SPSS19.0 (SPSS, Inc., Chicago, IL, USA) was 
used to process the data. Data obtained before 
and after treatment were compared by paired t-
test. Categorical data were compared by Chi-







After treatment, platelet and D-dimer levels were 
lower in the study than the control group (both p 
values < 0.05). Also, both the APTT and PT of 
the study group were better than those of the 
control group (both p values < 0.05). No 
coagulation index improved significantly after 
treatment in the control group (all p values > 
0.05). All coagulation indices were markedly 
better in the study than in the control group (all p 
values < 0.05) (Table 1). 
Comparison of clinical indices before and 
after treatment 
 
QoL score and KPS of the two groups did not 
differ before treatment; however, both scores 
improved significantly after treatment (p < 0.05). 
The improvement in the study group was 
significantly greater than that in the control group 
(p < 0.05; Table 2). 
 
Symptomatic supportive treatment  
 
Significantly fewer patients underwent 
symptomatic supportive treatment in the study 
than in the control group (p < 0.01, Table 3), 
suggesting that the TCM therapy lowered the risk 
of radiotherapy-induced toxic side effects. 
 
Incidence of adverse events  
 
The incidence of adverse events in the study 
group (6.70 %) was much lower than that in the 
control group (35 %; p < 0.05; Table 4). 
 
The incidence of genitourinary tract and upper 
digestive tract adverse events in the study group 
was significantly lower than that in the control 
group (p < 0.05), but no difference in adverse 
events of the lower digestive tract or skin was 
observed between the groups, indicating that 
Fuzheng Quyu therapy effectively prevented 
radiation-induced adverse events in the 
genitourinary and upper digestive tracts, but was 
less effective for relieving radiation-induced 




      Table 1: Coagulation index results for the two groups 
 
Group Study group Control group 
APTT (s) Before treatment 39.81±5.14 38.78±5.11 After treatment 30.24±3.46*# 35.79±4.99 
PT (s) Before treatment 17.43±3.16 17.86±3.31 After treatment 12.8±2.53*# 16.42±2.74 
D-dimer level (mg/L) Before treatment 0.69±0.47 0.73±0.49 After treatment 0.52±0.48*# 0.67±0.48 
Blood platelets (×109/L) Before treatment 295.72±100.24 288.99±98.75 After treatment 268.69±96.87*# 288.78±98.69 
       Note: *P < 0.05 compared with the level before treatment; #p < 0.05 compared with the control level 
 
            Table 2: Clinical indices before and after treatment (mean ± standard deviation, N = 60) 
 
Group QoL score KPS Before  After  Before  After  
Study  39.28 ± 3.68 41.48 ± 3.49 60.12 ± 2.61 75.67 ± 2.85 
Control 39.34 ± 3.33 36.57 ± 4.04 60.21 ± 2.53 56.95 ± 3.01 
T 0.067 4.994 0.090 14.131 
P-value >0.05 <0.05 >0.05 <0.05 
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                  Table 3: Drug intervention rates (N = 60) 
 





Study 5 55 0.83 
Control 17 43 28.33 
 
       Table 4: Incidence of adverse events after radiotherapy 
 







pelvic cavity) UGI 
Study  2 0 1 1 6.70% 
Control  10 1 8 2 35% 
X2 2.801 1.863 2.047 1.873 4.320 
p-value <0.05 >0.05 <0.05 >0.05 <0.05 




Cervical cancer is commonly encountered in the 
clinic and is usually treated via surgery and 
radiotherapy. Many physicians, both in China 
and elsewhere, have evaluated the various 
treatments in detail. Roh et al [9] performed a 
prospective, randomized controlled study on 86 
patients with cervical cancer who were randomly 
divided into a radical hysterectomy group (with 
pelvic nerve preservation) and a conventional 
radical hysterectomy group. Preservation of the 
cervical nerve improved the QoL. Zhou et al [10] 
randomly divided 67 patients with mid- and late-
stage cervical cancer into a group receiving 
three-dimensional conformal radiation therapy 
and chemotherapy and a group undergoing 
conventional radiotherapy and chemotherapy. 
The 3-year survival rates of the two groups were 
87.10 and 61.10 %, respectively (p = 0.017).  
 
Fabrini et al [11] found satisfactory outcomes for 
patients with stage Ib cervival cancer who 
exhibited high-level risk factors after 
radiochemotherapy. Kim et al [12] reported that 
postoperative adjuvant radiochemotherapy was 
both more effective and more tolerable than was 
radiotherapy in patients with moderate risk factor 
levels after cervical cancer surgery. However, 
patients may experience different extents of 
impairment, including reduced immunity, 
aggravated blood loss, nausea and emesis, 
when treated with the therapies discussed above 
[13]. Hence, it is important to identify safer and 
more effective therapies. 
 
Recently, Fuzheng Quyu (a TCM) has been 
shown to be of outstanding utility in patients 
undergoing chemotherapy after cervical cancer 
surgery. The principle of such therapy is that a 
disease should be treated by considering its 
origin. The treatment addresses both the 
symptoms and root causes of the disease, 
activating the blood, eliminating stasis, 
nourishing the spleen and tonifying the kidney 
[14]. With regard to the individual components of 
the prescription, Scutellaria baicalensis tonifies 
the spleen, increases vital energy, enhances 
immunity, activates lymphocyte phagocytosis 
and reduces the toxic side effects of 
radiotherapy.  
 
Chinese yam imparts vital energy and renders 
the temperament more phlegmatic. A 
glycoprotein therein increases the rate of 
phagocytosis by white blood cells. Lycium 
barbarum L. nourishes the kidney and liver, 
removes heat, eliminates dryness, thoroughly 
scavenges free radicals, treats tissue impairment 
and improves immunity. Angelica sinensis 
relieves anemia by reducing the elimination of 
red blood cells. Rhizoma sparganii and Curcuma 
zedoary improve serum resistance to 
inflammation and infection. The combination of 
all of these herbs enhances patient recovery, 
improves immunity, regulates neural and 
endocrine functions, reduces adverse reactions 
and platelet aggregation, prevents fibrosis, kills 
tumor cells, increases blood flow and improves 
blood circulation. 
 
Blood rheology indices of cancer patients differ 
significantly from those of normal control; the 
differences become more obvious as the disease 
progresses [15]. Cancer patients prefer 
chemotherapy to radiotherapy; however, 
chemotherapy cannot relieve hypercoagulation. 
TCMs that activate the blood and eliminate stasis 
can inhibit platelet aggregation, reduce blood 
viscosity, relieve hypercoagulation, correct blood 
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stasis syndrome and improve QoL [16]. We 
found that after treatment, coagulation indices 
such as the D-dimer level and platelet count 
were much lower in the study group than in the 
control group. Moreover, both the APTT and PT 
also improved markedly in the study group, 
reflecting improvements in the hypercoagulation 
status and the extent of microcirculatory 
disturbance. Fuzheng Quyu given during 
postoperative chemotherapy also improved the 
Karnofsky and QoL scores and greatly reduced 
the incidence of toxic side reactions in the 
genitourinary and upper gastrointestinal tracts (p 
< 0.05). This may be because Fuzheng Quyu 
adjusts the internal environment, improves 
haematopoietic functions, enhances cellular 
immunity and relieves emesis and haemographic 
decline [17]. 
 
Limitations of the study 
 
Although Fuzheng Quyu therapy improved the 
QOL in patients undergoing radiotherapy after 
cervical carcinoma surgery, relieved 
hypercoagulation and prevented and relieved 
toxic and side effects, the curative effects in only 
one disease case were evaluated as a result of 
time and other constraints. Thus, long-term 
observations and follow-up are lacking. These 
preliminary results suggest that Fuzheng Quyu 
therapy improves patient immunity, but the 





A herbal therapy designed to nourish vital energy 
and eliminate blood stasis relieves clinical 
symptoms, improves QoL and lowers the 
incidence of adverse events in patients 
undergoing radiotherapy after cervical cancer 
surgery. However, further clinical investigations 
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